Skip to main content
. Author manuscript; available in PMC: 2012 Dec 2.
Published in final edited form as: J Proteome Res. 2011 Oct 21;10(12):5463–5471. doi: 10.1021/pr200718p

Table 2.

Pathways perturbed by lovastatin treatment, as identified by IPA.

Ingenuity Canonical Pathways Proteins
Estrogen Receptor Signaling TAF9, SRA, general transcription factor TFIIB, MED1, MED12
Glutamate Metabolism GS, γ-ECS
Protein Ubiquitination Pathway BIRC6, USP10, DNAJC2, UBE2S, UBE2J1, HLA-C
Cholesterol Biosynthesis HMGCS, FDFT1
EIF2 Signaling EIF3G, EIF4G1, EIF2A